Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-03-01 Capital/Financing Update
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca prices a $2.25bn bond offering
Capital/Financing Update Classification · 1% confidence The document is a formal announcement released via RNS (London Stock Exchange news service) on March 1, 2023. The content explicitly details the pricing of a $2.25bn three-tranche global bond offering by AstraZeneca Finance LLC, including coupon rates, maturity dates, and references to SEC filings (Form F-3 shelf registration). This activity—raising capital through debt issuance—directly corresponds to the definition of a Capital/Financing Update. Although it is a regulatory announcement (RNS), the specific nature of the content (bond pricing) makes 'CAP' a more precise classification than the general 'RNS' fallback. The document length is relatively short (under 5,000 characters) and serves as a direct announcement of the financing event, not a comprehensive report.
2023-03-01 English
FWP
Regulatory Filings
2023-03-01 English
424B2
Prospectus
2023-02-28 English
ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING
Foreign Filer Report
2023-02-24 English
AstraZeneca prices a EUR1.5bn bond offering
Capital/Financing Update Classification · 1% confidence The document is a short announcement (3270 characters) released via RNS (Regulatory News Service) on February 24, 2023. The title is "AstraZeneca prices €1.5 billion bond offering." The content details the successful pricing and issuance of fixed-rate notes (€750 million each) and mentions the intended use of proceeds (general corporate purposes, including refinancing). This clearly falls under financing activities and capital structure changes. The most specific category is 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP more precise than the general RNS fallback.
2023-02-24 English
ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET
Foreign Filer Report
2023-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.